SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Shanghai Allist Pharmaceuticals Co., Ltd. Share Price
Equities
688578
CNE100005XJ7
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.14 CNY | -0.76% |
|
+3.32% | +53.96% |
| Sales 2023 | 2.01B 279M 22.22B | Sales 2024 * | 2.96B 410M 32.7B | Capitalization | 28.86B 3.99B 319B |
|---|---|---|---|---|---|
| Net income 2023 | 645M 89.27M 7.12B | Net income 2024 * | 1.04B 144M 11.45B | EV / Sales 2023 | 9.32 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 9.75 x |
| P/E ratio 2023 |
29.1
x | P/E ratio 2024 * |
27.8
x | Employees | 870 |
| Yield 2023 |
0.96% | Yield 2024 * |
0.78% | Free-Float | 34.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.76% | ||
| 1 week | +3.32% | ||
| Current month | +3.32% | ||
| 1 month | +37.34% | ||
| 3 months | +53.89% | ||
| 6 months | +69.10% | ||
| Current year | +53.96% |
1 week
62.15
68.87
1 month
45.3868.87
Current year
32.2568.87
1 year
22.1668.87
3 years
14.8168.87
5 years
14.8168.87
10 years
14.8168.87
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Hao Du
CEO | Chief Executive Officer | 70 | 21/03/04 |
Feng Xu
BRD | Director/Board Member | 59 | 31/12/16 |
Jie Hu
BRD | Director/Board Member | 49 | 24/06/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Yan
BRD | Director/Board Member | 42 | 27/11/19 |
Jin Hao Du
CEO | Chief Executive Officer | 70 | 21/03/04 |
Rong Gang Xie
BRD | Director/Board Member | 39 | 27/11/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 64.14 | -0.76% | 10 536 670 |
| 09/05/24 | 64.63 | +0.02% | 9,733,446 |
| 08/05/24 | 64.62 | -2.18% | 9,710,229 |
| 07/05/24 | 66.06 | -2.25% | 13,654,040 |
| 06/05/24 | 67.58 | +8.86% | 16,658,250 |
End-of-day quote Shanghai S.E., May 09, 2024
More quotes
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
64.14
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +53.96% | 4.03B | |
| +3.26% | 108B | |
| +11.19% | 104B | |
| +1.28% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -9.61% | 17.64B | |
| +4.45% | 14.05B | |
| +34.81% | 12.51B |
- Stock Market
- Equities
- 688578 Stock
